Pharsight

Pliaglis patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5919479 TARO Noninvasive dermal anesthetics
Jul, 2015

(8 years ago)

US6528086 TARO Methods and apparatus for drug delivery involving phase changing formulations
Sep, 2019

(4 years ago)

US10603293 TARO Solid-forming local anesthetic formulations for pain control
Jan, 2031

(6 years from now)

US10751305 TARO Solid-forming topical formulations for pain control
Jan, 2031

(6 years from now)

US10350180 TARO Solid-forming local anesthetic formulations for pain control
Jan, 2031

(6 years from now)

Pliaglis is owned by Taro.

Pliaglis contains Lidocaine; Tetracaine.

Pliaglis has a total of 5 drug patents out of which 2 drug patents have expired.

Expired drug patents of Pliaglis are:

  • US5919479
  • US6528086

Pliaglis was authorised for market use on 29 June, 2006.

Pliaglis is available in cream;topical dosage forms.

The generics of Pliaglis are possible to be released after 14 January, 2031.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using LIDOCAINE; TETRACAINE ingredient

Market Authorisation Date: 29 June, 2006

Treatment: NA

Dosage: CREAM;TOPICAL

More Information on Dosage

PLIAGLIS family patents

Family Patents